Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brimonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 20/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 19/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 19/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 15/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 13/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brimonidine SCHEMBL20511531 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL29374525 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616115 | 0.99 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL1685506 | 0.99 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616188 | 0.92 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616237 | 0.91 | ADRA2A (0.83) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616205 | 0.90 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL20511553 | 0.89 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616277 | 0.89 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616267 | 0.88 | ADRA2A (0.78) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14561 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144679-A1 | Vasoconstriction for eye treatments | BELKIN VISION LTD. (IL) | 2026-05-28 | — | — | US | claimed |
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| WO-2026102187-A1 | ENGINEERED VIRUS-LIKE PARTICLES COMPRISING A BASE EDITOR FOR THE TREATMENT OF GLAUCOMA, AND APPLICATIONS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4736853-A2 | DEGRADANT COMPOUND IN A MEDICAMENT | Visus Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260090984-A1 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | MEDIPRINT OPHTHALMICS INC. (US) | 2026-04-02 | — | — | US | claimed |
| US-20260083746-A1 | REDUCED DOSING REGIMENS FOR GLAUCOMA TREATMENT | HARROW IP LLC (US) | 2026-03-26 | — | — | US | claimed |
| US-12582603-B2 | Ophthalmic pharmaceutical composition containing a combination of brinzolamide and brimonidine and method of preparation thereof | NTC S.R.L. (IT) | 2026-03-24 | — | — | US | claimed |
| EP-0630262-A1 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1994-12-28 | — | — | EP | claimed |
| US-5275820-A | Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles | ALLERGAN, INC. (US) | 1994-01-04 | — | — | US | claimed |
| WO-1993025199-A1 | ALPHA-2-ADRENERGIC AGONISTS FOR TREATING PRESBYOPIA | TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) | 1993-12-23 | — | — | WO | claimed |
| EP-0564537-A1 | STABLE SUSPENSION FORMULATIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1993-10-13 | — | — | EP | claimed |
| WO-1993017716-A1 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1993-09-16 | — | — | WO | claimed |
| EP-0537165-A1 | POLYMERIC DRUG DELIVERY SYSTEM | ALLERGAN, INC. (US) | 1993-04-21 | — | — | EP | claimed |
| EP-0537165-A4 | POLYMERIC DRUG DELIVERY SYSTEM. | ALLERGAN INC (US) | 1993-02-24 | — | — | EP | claimed |
| WO-1992011871-A1 | STABLE SUSPENSION FORMULATIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICAL COMPOUNDS | ALLERGAN, INC. (US) | 1992-07-23 | — | — | WO | claimed |
| WO-1991016869-A1 | POLYMERIC DRUG DELIVERY SYSTEM | ALLERGAN, INC. (US) | 1991-11-14 | — | — | WO | claimed |
| US-4145421-A | AMINOIMIDAZOLINE-SUBSTITUTED QUINOXALINES | SANDOZ LTD. (CH) | 1979-03-20 | — | — | US | claimed |